Eyewire News

Featured Story

Innovent's Sycume Meets Primary Endpoint in Phase 3 Trial for Inactive Thyroid Eye Disease (TED) image

10.09.2026

Innovent's Sycume Meets Primary Endpoint in Phase 3 Trial for Inactive Thyroid Eye Disease (TED)

Innovent Biologics announced that Sycume (teprotumumab N01 injection; IBI311), its independently developed recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, met the primary endpoint in the phase 3 RESTORE-3 clinical trial evaluating the treatment in Chinese patients with inactive thyroid eye disease (TED). The multicenter, randomized, double-blind, placebo-controlled study demonstrated statistically significant improvements in proptosis response rates and reductions in proptosis at Week 24 compared with placebo.

Read Story

Latest News Stories

Glaukos Reports Positive Phase 4 Results for iDose TR Combined with Cataract Surgery image

10.09.2026

Glaukos Reports Positive Phase 4 Results for iDose TR Combined with Cataract Surgery

Perceive Bio Completes Phase 2a Enrollment in VOY-101 Gene Therapy Study for Geographic Atrophy image

10.09.2026

Perceive Bio Completes Phase 2a Enrollment in VOY-101 Gene Therapy Study for Geographic Atrophy

10.09.2026

BioTissue to Present Phase 2 TTAX03 Dry Eye Disease Study Results at AAO

10.09.2026

Carrot to Acquire GreenMan Vision, Expanding VR Platform into IOL Simulation for Cataract Surgery

10.09.2026

Stuart Therapeutics Submits FDA Amendment to Evaluate ST-100 in Corneal Wound Healing

10.09.2026

RadiusXR and Topcon Healthcare Introduce InspirePRO Wearable Perimeter at AAO

Haag-Streit Launches Eyesi Surgical 3.0 Virtual Reality Training Platform at AAO image

10.09.2026

Haag-Streit Launches Eyesi Surgical 3.0 Virtual Reality Training Platform at AAO

Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies image

10.09.2026

Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies

Iantrek Reports 37.2% IOP Reduction at 6 Months with Bio-Reinforced Canaloplasty image

10.08.2026

Iantrek Reports 37.2% IOP Reduction at 6 Months with Bio-Reinforced Canaloplasty

CooperVision Highlights Global Partnerships Expanding Access to Eye Care on World Sight Day image

10.08.2026

CooperVision Highlights Global Partnerships Expanding Access to Eye Care on World Sight Day

Glaukos Reports 3-year Epioxa Data Showing Sustained Corneal Flattening in Keratoconus image

10.07.2026

Glaukos Reports 3-year Epioxa Data Showing Sustained Corneal Flattening in Keratoconus

Bausch + Lomb to Present IOL, Glaucoma and Ocular Surface Data at AAO image

10.07.2026

Bausch + Lomb to Present IOL, Glaucoma and Ocular Surface Data at AAO

Atsena Reports Preliminary ATSN-201 Results in X-linked Retinoschisis image

10.07.2026

Atsena Reports Preliminary ATSN-201 Results in X-linked Retinoschisis

10.07.2026

Study Links GLP-1 Use to Earlier Fellow-Eye NAION Involvement

Volk Optical Launches ClearField Pro Lens for Retinal Examination and Laser Treatment image

10.07.2026

Volk Optical Launches ClearField Pro Lens for Retinal Examination and Laser Treatment

10.06.2026

2026 Nobel Prize in Medicine Recognizes Optogenetics Pioneers

Sight Sciences Launches Omni Ultra Surgical System for Implant-Free Glaucoma Intervention image

10.06.2026

Sight Sciences Launches Omni Ultra Surgical System for Implant-Free Glaucoma Intervention

Topcon Healthcare Launches Oku Digital Health to Connect Ocular Data with Systemic Disease Insights image

10.06.2026

Topcon Announces Global Launch of Oku Digital Health to Connect Ocular Data with Systemic Disease Insights

Alcon to Showcase Surgical, Retinal, Glaucoma, and Dry Eye Innovations at AAO image

10.06.2026

Alcon to Showcase Surgical, Retinal, Glaucoma, and Dry Eye Innovations at AAO

View More